SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is currently trending following a reported test setback where its Neutron rocket's Stage 1 tank ruptured during qualification trials. This development has led to market volatility, with a divided community either 'buying the dip' on confidence in defense contracts and future launches, or expressing caution over valuation and anticipating further price declines. Discussion remains intense as investors weigh short-term challenges against the company's long-term potential in the burgeoning space sector.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is trending as the community keenly watches significant regulatory developments, including modernized deep-sea mining permit processes from NOAA and an upcoming Congressional hearing featuring the CEO. This activity is fueled by a growing recognition of deep-sea minerals as a national security priority and strong market expectations for accelerated project timelines.

Venture Global, Inc. engages in the development and construction of liquefied natural gas production, establishing us as a rapidly growing company delivering critical LNG to the world. It projects include Calcasieu, Plaquemines, CP2, CP3 and Delta projects. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global is significantly trending after announcing a favorable arbitration award against Repsol, validating its operational conduct regarding Calcasieu Pass LNG sales. This pivotal win has fueled intense bullish sentiment, with the community actively discussing a potential substantial short squeeze and a strong stock rebound. Many foresee continued upside, driven by the company's execution and persistent global demand for LNG.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is experiencing a significant surge, driven by recent analyst upgrades, robust server CPU demand, and growing optimism for its advanced 18A process technology and Panther Lake processors. The community is actively discussing massive gains and long-term potential fueled by strategic government backing, though some anticipate a "sell the news" reaction as investors await the upcoming earnings report.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending due to significant insider buying, with CEO Ryan Cohen substantially increasing his stake over consecutive days, joined by another board member. This show of conviction is fueling community speculation about a potential short squeeze and a "bottom" being found, reminiscent of past meme stock events. Many are discussing this as a direct challenge to short sellers and a strategic move by management.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

KENDU CRYPTO is trending as its dedicated community relentlessly builds a "permissionless brand" with tangible real-world products and ongoing initiatives, from Kendu Spice to entertainment. This active, 'delulu' community emphasizes a long-term vision, consistent development across various blockchains, and a unique commitment to creating lasting value beyond typical crypto hype. The collective effort and daily progress continue to drive robust discussion and conviction among its supporters.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is experiencing a significant surge, driven by impressive long-term data from its personalized cancer vaccine candidate in partnership with Merck, demonstrating sustained efficacy against high-risk melanoma. This breakthrough is igniting widespread community discussion about a substantial short squeeze and the company's valuation, as investors anticipate the transformative potential of its mRNA pipeline beyond prior vaccine successes.

PAVmed, Inc. is a multi-product life sciences company, which engages in the innovation, development, acquisition, and commercialization of products that target unmet medical needs with large addressable market opportunities. Its products include Lucid Diagnostics and Veris Health. The company was founded by Lishan Aklog and Brian J. deGuzman on June 26, 2014 and is headquartered in New York, NY.

PAVmed Inc

PAVmed is experiencing extreme volatility and a surge in trading volume following news that its subsidiary, Lucid Diagnostics, secured a significant contract with the U.S. Department of Veterans Affairs for its EsoGuard Esophageal DNA Test. This development, coupled with its notably low share float and recent reverse split, has ignited intense speculative trading, leading many to label it a prime short squeeze candidate. While some foresee substantial further gains, others remain cautious, warning of a potential pump and dump scenario amidst reports of heavy selling pressure.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is trending due to rumors of a potential acquisition by Zydus Lifesciences, amplified by recent positive updates including a significant patent extension to 2041 for its key therapies and bullish revenue guidance for IBSRELA. The community is actively discussing valuation, believing the company is fundamentally undervalued given its strengthened intellectual property and expanding market potential for its approved drugs.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Fueling intense debate, Sandisk ($SNDK) is experiencing a historic surge, largely attributed to robust demand for memory and data storage driven by AI infrastructure and tight supply conditions. Community sentiment is bifurcated, with bulls reveling in its "unstoppable" trajectory and a potential short squeeze, while bears warn of an unsustainable "bubble" and impending correction given its extraordinary valuation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Indaptus Therapeutics, Uipath, Trinity Biotech, Sable Offshore And McDonald's: Why These 5 Stocks Are On Investors' Radars Today

INDP, PATH, TRIB, SOC, MCD were among the stocks seen among investors on Tuesday, Dec. 23, 2025.read more...

<ul class="summary-bullets"><li>Trinity Biotech’s shares were up nearly 47% in Tuesday’s midday trade after the company announced that it had secured an order for nine million units of its TrinScreen HIV rapid diagnostic test.</li><li>Starfighters Space shares were down over 51% in Tuesday’s midday session, taking a breather after a massive 371% rally on Monday.</li><li>VisionWave shares were up nearly 8% in Tuesday’s midday trade after the company announced the issuance of a new patent that covers the systems and methods for real-time movement, position detection, and imaging technology.</li></ul>U.S. equities traded in the green on Tuesday noon amid optimism about a Santa Claus rally, with the Dow Jones Industrial Average, S&amp;P 500, and the Nasdaq Composite on course for their fourth consecutive winning session.Earlier in the day, the Bureau of Economic Analysis&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/us-gdp-q3-december-2025/cLep8gzREuU">reported</a> that the U.S. economy grew at an annualized rate of 4.3%, higher than the Dow Jones forecast of 3.2%, as&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/us-gdp-q3-december-2025/cLep8gzREuU">cited</a> by MarketWatch.The&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF</a> (SPY), which mirrors the S&amp;P 500 index, was up 0.28% at the time of writing, while the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust</a> (QQQ), which mirrors the Nasdaq 100 index, gained 0.25%. The&nbsp;<a href="https://stocktwits.com/symbol/DIA">SPDR Dow Jones Industrial Average ETF Trust</a> (DIA), which tracks the Dow Jones Industrial Average, rose 0.18%.<h2 class="st-heading-2">Here are the top stocks making the biggest moves in Tuesday’s midday trade:</h2><a href="https://stocktwits.com/symbol/NVO">Novo Nordisk AS (NVO)</a>Novo Nordisk shares were up more than 9% in Tuesday’s midday session after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-stock-soars-after-hours-as-fda-greenlights-wegovy-pill-for-weightloss/cLeFw1kREu2">said</a> that its Wegovy pill for weight loss has been approved by the U.S. Food and Drug Administration (FDA), making it the first oral GLP-1 class drug for weight management approved by the agency.<a href="https://stocktwits.com/symbol/NVO">NVO stock</a> is down 39% year-to-date.<a href="https://stocktwits.com/symbol/TRIB">Trinity Biotech Plc. (TRIB)</a>Trinity Biotech’s shares were up nearly 47% in Tuesday’s midday trade after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-trinity-biotech-stock-surge-nearly-50-in-premarket-today/cLepnI7REuv">announced</a> that it had secured an order for nine million units of its TrinScreen HIV rapid diagnostic test, scheduled for delivery in the fourth quarter (Q4) of 2025 and the first quarter (Q1) of 2026.<a href="https://stocktwits.com/symbol/TRIB">TRIB stock</a> is up 48% year-to-date.<a href="https://stocktwits.com/symbol/FJET">Starfighters Space Inc. (FJET)</a>Starfighters Space shares were&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/fjet-stock-takes-a-breather-post-massive-rally/cLepsN8REH7">down</a> over 51% in Tuesday’s midday session, taking a breather after a massive 371% rally on Monday. The company laid out its 2026 plans, stating that the convergence of government demand, growth in the commercial space segment, and public market access following its IPO positions it well.<a href="https://stocktwits.com/symbol/FJET">FJET stock</a> is up 56% year-to-date.<a href="https://stocktwits.com/symbol/VWAV">VisionWave Holdings Inc. (VWAV)</a>VisionWave shares were up nearly 8% in Tuesday’s midday trade after the company announced the issuance of a new patent that covers the systems and methods for real-time movement, position detection, and imaging technology.<a href="https://stocktwits.com/symbol/VWAV">VWAV stock</a> is up 263% year-to-date.<a href="https://stocktwits.com/symbol/NOW">ServiceNow Inc. (NOW)</a>ServiceNow shares were down nearly 3% in Tuesday’s midday session after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/service-now-acquires-armis-in-7-75-billion-deal-to-strengthen-ai-powered-security-platform/cLepYSLREHb">announced</a> the acquisition of cybersecurity startup Armis in a $7.75 billion deal as it looks to bolster its offerings amid rising threats due to the expanding use of AI.<a href="https://stocktwits.com/symbol/NOW">NOW stock</a> is down 28% year-to-date.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/fjet-stock-takes-a-breather-post-massive-rally/cLepsN8REH7">FJET Stock Takes A Breather Post Massive Rally – Starfighters Space Releases 2026 Plans After Stock Market Debut</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A bull statue and a bear statue stand outside the Frankfurt Stock Exchange on April 7, 2025 in Frankfurt, Germany

Novo Nordisk, Trinity Biotech, Starfighters Space, VisionWave, ServiceNow: Stocks Making The Biggest Moves Today

Novo Nordisk shares were up more than 9% in Tuesday’s midday session after the company said that the U.S. FDA has approved its Wegovy pill for weight loss.

Equity

<ul class="summary-bullets"><li>Trinity posted a 32% sequential increase in third-quarter revenue to $14.3 million, driven by a $2.1 million increase in rapid HIV test sales.</li><li>The company entered into new financing agreements with funds managed by Perceptive Advisors.</li><li>The deal includes $5 million in new term-loan funding and up to $60 million in elective equitization capacity.</li></ul>Trinity Biotech (TRIB) shares surged nearly 50% in premarket trading on Tuesday, after the company said it had secured an order for 9 million units of its TrinScreen HIV rapid diagnostic test.The WHO-prequalified rapid diagnostic test is designed for high-volume screening programs and will be produced through the company’s recently approved outsourced manufacturing process. Trinity Biotech expects to fulfil the order across the fourth quarter of 2025 and the first quarter of 2026, with the contract set to support revenue growth.<a href="https://stocktwits.com/symbol/TRIB">Trinity Biotech</a> also posted a 32% sequential increase in third-quarter revenue to $14.3 million, driven by a $2.1 million increase in rapid HIV test sales, while adjusted EBITDA improved to a $0.5 million profit from a $2.1 million loss in Q2.The company said it continues to advance its transformation plan after securing key regulatory approvals, including WHO authorization to outsource production of its Uni-Gold HIV rapid test. These milestones are expected to drive efficiency gains and support rising adjusted EBITDA through the first half of 2026."Our operating and financial improvement in Q3 2025 was encouraging, in particular the achievement of positive Adjusted EBITDA. This gives us confidence that our Comprehensive Transformation Plan is on track and, when combined with our exciting innovation agenda, leaves the business well positioned for further progress in 2026,” said John Gillard, CEO of Trinity Biotech. &nbsp;<h2 class="st-heading-2">Trinity's Financing Plans</h2>Trinity Biotech also entered into new financing agreements with funds managed by Perceptive Advisors to strengthen liquidity and improve capital structure flexibility.&nbsp;The deal includes $5 million in new term-loan funding and up to $60 million in elective equitization capacity, which could lower debt and interest costs. The agreements also introduce equity-based settlement options for certain obligations, supporting Trinity Biotech’s long-term growth and investment plans.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment flipped to 'extremely bullish' from 'extremely bearish' a day earlier, amid 'extremely high' message volumes.<img src="https://news.stocktwits-cdn.com/TRIB_png_e777e3d7ee.webp" alt="TRIB.png">One user sees $1.75 as a key resistance point.<stembedurl>https://stocktwits.com/TeamBullish/message/639966430</stembedurl>Year-to-date, the stock has gained 43%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Did Trinity Biotech Stock Surge Nearly 50% In Premarket Today?

Trinity Biotech (TRIB) shares surged nearly 50% in premarket trading on Tuesday, after the company said it had secured an order for 9 million units of its TrinScreen HIV rapid diagnostic test.

The company secured an order for 9 million units of its TrinScreen HIV rapid diagnostic test.

Trinity Biotech's Redesigned CGM Sensor Favored by New Clinical Data

TRIB's needle-free CGM+ sensor shows accurate 15-day results with no calibration, slashing costs and boosting access.

Trinity Biotech&nbsp;notched its best session on record on Thursday after its New York reference laboratory received approval from the New York State Department of Health to begin offering the FDA-cleared PreClara Ratio biomarker test for assessing the risk of preeclampsia.&nbsp;Shares of Trinity Biotech soared 89.1% to $1.9 on Thursday, marking its best session since the company’s launch in 1992, before sliding 16% to $1.6 in after-hours trading. Additionally, trading volume in Trinity surged to 208.5 million shares on Thursday, more than 1,160 times its average daily volume of 178,948.The service, which has a planned release in the third quarter (Q3) of 2025, is expected to support clinicians in making more rapid and informed decisions for patients hospitalized with hypertensive disorders of pregnancy, a complex set of conditions that impacts approximately 500,000 women annually in the U.S.&nbsp;The test, by estimating the risk of progression to severe preeclampsia, can enable earlier and more precise interventions.&nbsp;Research published in March estimated the potential to achieve more than $10 million in neonatal cost savings per 1,000 patients with the test as part of standard care, largely due to a reduction in preterm births and NICU days.The approval also paves the way for Trinity's expected launch of PrePsia, its proprietary technology that screens for preeclampsia risk earlier in pregnancy.&nbsp;Preeclampsia is estimated to affect 5–8% of pregnancies. The condition is a major driver of maternal and neonatal complications in the U.S., accounting for approximately 11% of maternal deaths and 15% of premature births.The PreClara Ratio is designed for use alongside other laboratory tests and clinical assessments in women between 23 and nearly 35 weeks of pregnancy who are hospitalized with hypertensive disorders.&nbsp;It calculates a ratio from specific blood test results to estimate the short-term risk of developing severe preeclampsia.On Stocktwits, retail sentiment for Trinity Biotech was ‘extremely bullish’ amid a 7,211% surge in 24-hour message volume.One user remarked that they expected Trinity Biotech to climb back over $3.00 the next day, urging others to “buy the dips and hold,” adding that all short shares were accounted for and the stock “can rip and halt like it did today.”&nbsp;<stembedurl>https://stocktwits.com/Magicians/message/625281470</stembedurl>Another user speculated that the sharp rise could be followed by a dilution announcement, noting the stock was now “going down on huge volume.”&nbsp;<stembedurl>https://stocktwits.com/Huskersnsaints/message/625247540</stembedurl>A third user predicted it could “easily break $4.00” going into the next session, recommending buying at market price and holding.<stembedurl>https://stocktwits.com/Magicians/message/625225289</stembedurl>Trinity Biotech’s stock has more than doubled so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Shares of Trinity Biotech (TRIB) soared 89.1% to $1.9 on Thursday, marking its best session since the company’s launch in 1992. (Photo credit: Getty Images)

Trinity Biotech Stock Marks Best Day Ever On New York Greenlight For Pregnancy Risk Test; Retail Sees More Upside

Trading volume in Trinity Biotech spiked to more than 1,160 times its daily average after regulators cleared the PreClara Ratio test, which helps doctors identify pregnant patients at risk of developing severe preeclampsia.

Three nano-cap healthcare stocks drew massive attention from retail investors on Stocktwits Tuesday, though not all for positive reasons.Trinity Biotech (<a href="https://stocktwits.com/symbol/TRIB">TRIB</a>)&nbsp;Shares of the medical diagnostic products maker saw a staggering 15,550% jump in retail message volume after the company released “compelling” results from a study on its next-generation continuous glucose monitoring system.&nbsp;The device, designed for real-time diabetes management, demonstrated superior signal quality, accuracy, and consistency in a trial involving 30 diabetic participants.&nbsp;The system features a reusable applicator and rechargeable wearable transmitter, reducing costs by eliminating disposable components.&nbsp;Trinity said it remains on track to seek regulatory approval in the EU by 2025 and the U.S. by 2026.&nbsp;Shares fell over 13% premarket Wednesday.Silexion Therapeutics (<a href="https://stocktwits.com/symbol/SLXN">SLXN</a>)&nbsp;The cancer-focused biotech firm’s ticker saw a 9,060% surge in retail message volume as its stock more than doubled Tuesday following promising preclinical data for its tumor drug candidate SIL-204.&nbsp;The company reported that the extended-release formulation of SIL-204 reduced tumor growth by more than 50% after 30 days, with around 50% of tumors showing complete necrosis in human pancreatic models.&nbsp;Additionally, an injectable version of the drug candidate showed tumor growth inhibition in metastatic pancreatic mouse models.&nbsp;The stock continued its rally, gaining over 70% premarket Wednesday.Sharps Technology (<a href="https://stocktwits.com/symbol/STSS">STSS</a>)&nbsp;The medical packaging firm experienced a 6,233% surge in retail message volume, but for the wrong reasons.&nbsp;Shares plunged nearly 70% to a record low on Tuesday after the company announced a $20 million public offering of 14,285,714 Common Units.&nbsp;Each unit consists of one share of common stock, one Series A warrant, and one Series B warrant, priced at $1.40 per unit, a 4.1% discount to Monday’s close.&nbsp;The company said the proceeds would be used for general corporate purposes and working capital.&nbsp;The stock continued to slide, down over 2% premarket Wednesday.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stockbroker analyzing financial stock market with reflection on eyeglasses. Photo via Westend61 on Getty Images

TRIB, SLXN, STSS: Why Retail Chatter On 3 Nano-Cap Healthcare Stocks Exploded Over 6000%

“Compelling” results from a study, promising pre-clinical data and a public offering got Stocktwits investors buzzing on Tuesday.

Trinity Biotech Plc engages in the development, manufacture, and marketing of medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market. It operates through the Americas and Rest of World geographical segments. The company was founded by Ronan O'Caoimh and Denis R. Burger in June 1992 and is headquartered in Bray, Ireland.

Trinity Biotech Plc - ADR

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

TRIB
Trinity Biotech plc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest TRIB News

TRIBTrinity Biotech plc